FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2570464272> ?p ?o ?g. }

• W2570464272 endingPage "S903" @default.
• W2570464272 startingPage "S902" @default.
• W2570464272 abstract "ABP 215 is a biosimilar candidate that is similar to bevacizumab, a VEGF inhibitor, in analytical and functional comparisons. Pharmacokinetic similarity between ABP 215 and bevacizumab has been demonstrated in a phase 1 study. Here we present results from a pivotal phase 3 clinical study in non–small-cell lung cancer (NSCLC). In this double-blind, active-controlled study in adults with non-squamous NSCLC receiving first-line chemotherapy with carboplatin and paclitaxel, subjects were randomized (1:1) to receive investigational product (IP; ABP 215 or bevacizumab 15 mg/kg) Q3W for 6 cycles as an IV infusion. Clinical equivalence was demonstrated by comparing the 2-sided 90% confidence interval (CI) of the risk ratio (RR) of the objective response rate (ORR; primary endpoint) with pre-specified margin of (0.67, 1.5) Secondary endpoints were risk difference (RD) of the ORR, duration of response (DOR), progression-free survival (PFS), treatment-emergent adverse events, and overall survival (OS). A total of 642 subjects (ABP 215 [Arm 1], n=328; bevacizumab [Arm 2], n=314) were randomized. Demographic and baseline characteristics were balanced between arms. There were 128 (39.0%) responders in Arm 1 and 131 (41.7%) responders in Arm 2. The RR for ORR was 0.93 (90%CI, 0.80–1.09). The RD for ORR was −2.90% (90%CI, −9.26%–3.45%). Among the responders the estimated median DOR was 5.8 months in Arm 1 versus 5.6 months in Arm 2. The estimated median PFS in Arm 1 was 6.6 months versus 7.9 months in Arm 2; the analysis included all 256 PFS events, 131 (39.9%) in Arm 1 and 125 (39.8%) in Arm 2. The safety population included 324 treated subjects in Arm 1 and 309 in Arm 2; 139 (42.9%) subjects in Arm 1 and 137 (44.3%) in Arm 2 experienced grade ≥3 TEAEs. TEAEs leading to IP discontinuation affected 61 (18.8%) subjects in Arm 1 and 53 (17.2%) in Arm 2; 85 (26.2%) subjects in Arm 1 and 71 (23.0%) in Arm 2 experienced at least one serious AE; 13 (4.0%) in Arm 1 and 11 (3.6%) in Arm 2 had a fatal TEAE. OS analysis included 79 deaths, 43 (13.3%) in Arm 1 and 36 (11.7%) in Arm 2. Binding antibodies developed during the study in 4 (1.4%) subjects in Arm 1 versus 7 (2.5%) in Arm 2; no subject tested positive for neutralizing antibodies. The study met the primary and secondary objectives demonstrating that ABP 215 and bevacizumab are clinically equivalent." @default.
• W2570464272 created "2017-01-13" @default.
• W2570464272 creator A5008737715 @default.
• W2570464272 creator A5013804417 @default.
• W2570464272 creator A5014416915 @default.
• W2570464272 creator A5025985477 @default.
• W2570464272 creator A5028746264 @default.
• W2570464272 creator A5029343418 @default.
• W2570464272 creator A5086174841 @default.
• W2570464272 date "2017-01-01" @default.
• W2570464272 modified "2023-09-30" @default.
• W2570464272 title "P2.03a-025 Randomized, Double-Blind, Phase 3 Study Comparing Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non-Squamous NSCLC" @default.
• W2570464272 doi "https://doi.org/10.1016/j.jtho.2016.11.1234" @default.
• W2570464272 hasPublicationYear "2017" @default.
• W2570464272 type Work @default.
• W2570464272 sameAs 2570464272 @default.
• W2570464272 citedByCount "1" @default.
• W2570464272 countsByYear W25704642722019 @default.
• W2570464272 crossrefType "journal-article" @default.
• W2570464272 hasAuthorship W2570464272A5008737715 @default.
• W2570464272 hasAuthorship W2570464272A5013804417 @default.
• W2570464272 hasAuthorship W2570464272A5014416915 @default.
• W2570464272 hasAuthorship W2570464272A5025985477 @default.
• W2570464272 hasAuthorship W2570464272A5028746264 @default.
• W2570464272 hasAuthorship W2570464272A5029343418 @default.
• W2570464272 hasAuthorship W2570464272A5086174841 @default.
• W2570464272 hasBestOaLocation W25704642721 @default.
• W2570464272 hasConcept C112705442 @default.
• W2570464272 hasConcept C126322002 @default.
• W2570464272 hasConcept C143998085 @default.
• W2570464272 hasConcept C168563851 @default.
• W2570464272 hasConcept C197934379 @default.
• W2570464272 hasConcept C203092338 @default.
• W2570464272 hasConcept C2776256026 @default.
• W2570464272 hasConcept C2776694085 @default.
• W2570464272 hasConcept C2777802072 @default.
• W2570464272 hasConcept C2778239845 @default.
• W2570464272 hasConcept C2779177807 @default.
• W2570464272 hasConcept C2781451048 @default.
• W2570464272 hasConcept C31760486 @default.
• W2570464272 hasConcept C44249647 @default.
• W2570464272 hasConcept C59491497 @default.
• W2570464272 hasConcept C71924100 @default.
• W2570464272 hasConcept C81729549 @default.
• W2570464272 hasConceptScore W2570464272C112705442 @default.
• W2570464272 hasConceptScore W2570464272C126322002 @default.
• W2570464272 hasConceptScore W2570464272C143998085 @default.
• W2570464272 hasConceptScore W2570464272C168563851 @default.
• W2570464272 hasConceptScore W2570464272C197934379 @default.
• W2570464272 hasConceptScore W2570464272C203092338 @default.
• W2570464272 hasConceptScore W2570464272C2776256026 @default.
• W2570464272 hasConceptScore W2570464272C2776694085 @default.
• W2570464272 hasConceptScore W2570464272C2777802072 @default.
• W2570464272 hasConceptScore W2570464272C2778239845 @default.
• W2570464272 hasConceptScore W2570464272C2779177807 @default.
• W2570464272 hasConceptScore W2570464272C2781451048 @default.
• W2570464272 hasConceptScore W2570464272C31760486 @default.
• W2570464272 hasConceptScore W2570464272C44249647 @default.
• W2570464272 hasConceptScore W2570464272C59491497 @default.
• W2570464272 hasConceptScore W2570464272C71924100 @default.
• W2570464272 hasConceptScore W2570464272C81729549 @default.
• W2570464272 hasIssue "1" @default.
• W2570464272 hasLocation W25704642721 @default.
• W2570464272 hasOpenAccess W2570464272 @default.
• W2570464272 hasPrimaryLocation W25704642721 @default.
• W2570464272 hasRelatedWork W1810708577 @default.
• W2570464272 hasRelatedWork W1997961771 @default.
• W2570464272 hasRelatedWork W2039727128 @default.
• W2570464272 hasRelatedWork W2139697170 @default.
• W2570464272 hasRelatedWork W2169335753 @default.
• W2570464272 hasRelatedWork W2287009164 @default.
• W2570464272 hasRelatedWork W2604148568 @default.
• W2570464272 hasRelatedWork W4231596293 @default.
• W2570464272 hasRelatedWork W4281766515 @default.
• W2570464272 hasRelatedWork W4312139687 @default.
• W2570464272 hasVolume "12" @default.
• W2570464272 isParatext "false" @default.
• W2570464272 isRetracted "false" @default.
• W2570464272 magId "2570464272" @default.
• W2570464272 workType "article" @default.